Our promise to you:
Guaranteed product quality, expert customer support.
Lp-PLA2, also known as platelet-activating factor acetylhydrolase or type VIIA PLA2, is encoded by Pla2g7 gene and composes of 441 amino acids, which is a unique member of PLA2 super-family. Lp-PLA2 is a Ca2+-independent phospholipase belonging to phospholipase A2 superfamily. The initial association between the Lp-PLA2 levels and the risk of cardiovascular disease was reported by the WOSCOPS (West of Scotland Coronary Prevention Study), subsequent studies also successfully reproduced these observations. According to previous clinical and epidemiological studies, Lp-PLA2 is an inflammatory marker and a risk factor for mortality from coronary heart disease, stroke, and cardiovascular disease (CVD), some scientific researches in different animal models have also shown that increasing serum level of Lp-PLA2 can mitigate vascular inflammation and attenuate atherosclerosis.
Lp-PLA2 and Atherosclerosis
Lp-PLA2 is recognized as a pro-atherogenic enzyme responsible for regulating lipid metabolism and inflammatory respond because of its capability of hydrolyzing platelet activating factor (PAF) and LDLC, both of which are considered to be detrimental to vessel wall. Intriguingly, a substantial amount of studies have gradually reported that the activity or mass of Lp-PLA2 is positively associated with the severity of atherosclerosis and CV risk, both of which play crucial roles in the development and progress of atherosclerosis. The atherogenic effect of Lp-PLA2 is largely associated with conventional atherogenic-lipids, and the effect of Lp-PLA2 on cardiovascular system outweighs the so-call anti-atherogenesis effect and has been evidenced by large number of scientific and clinical research.
Lp-PLA2 Secretion and Circulation in the Blood-Stream
In the bloodstream, Lp-PLA2 circulates by two-thirds bounding to the LDLs and one-third to HDLs. Plasma ultracentrifugation leads to partial separation of Lp-PLA2 from the lipoproteins indicating the presence of a dissociable and a non-dissociable form of the enzyme. The transition between them might be the mechanisms regulating the activity of Lp-PLA2 in vivo. The association with HDL and LDL is controlled by post-translational chemical modifications: glycosylation of specific residues decreases the association of Lp-PLA2 and lipoproteins, even though these changes do not seem to influence the enzyme secretion by the cells.
Figure 1. Pathogenic role of lipoprotein-associated phospholipase A2 in atherosclerosis development.